4.6 Article

NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing

期刊

THORAX
卷 68, 期 4, 页码 391-393

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2012-202376

关键词

-

资金

  1. Bayer PLC
  2. Sanofi Aventis
  3. GlaxoSmithKline
  4. Pfizer
  5. Novartis

向作者/读者索取更多资源

The National Institute for Health and Clinical Excellence recently published a clinical guideline on the management of venous thromboembolic disease and thrombophilia testing. Several stand-out recommendations are made which may be practice changing for many physicians, such as catheter-directed thrombolysis for ilio-femoral deep venous thrombosis, routine cancer screening and extended duration of anticoagulation for unprovoked events. In this article, we summarise the key points of the guideline and discuss remaining areas of controversy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据